The European evidence generation strategy lead for epilepsy and rare syndromes at UCB described some details about further epilepsy research and other explorations in the next few years. [WATCH TIME: 3 minutes]
Iryna Leunikava, MSc
Advertisement
The Europeanevidence generation strategy lead for epilepsy and rare syndromes at UCB Pharma.
Articles by Iryna Leunikava, MSc
The European evidence generation strategy lead for epilepsy and rare syndromes at UCB Pharma talked about positive results from observational studies assessing the impact of brivaracetam among patients with focal seizures, which was presented at AES 2023. [WATCH TIME: 5 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Key Clinical and Genetic Biomarkers in Huntington Disease Research: Sarah O'Shea, MD, MSc
2
A Step Forward in Multiple System Atrophy: Phase 2 Findings Reinforce ATH434’s Disease-Modifying Potential
3
De-Escalation Strategies in Multiple Sclerosis: Oral Therapies and Cladribine
4
COAST Trial: Evaluating Ozanimod Step-Down in Multiple Sclerosis
5
